LONDON (Reuters) – British scientists on Monday said that an antiviral drug commonly used to treat HIV had no beneficial effect in patients hospitalised with COVID-19 in a large scale randomised trial.
Scientists running the RECOVERY trial at the University of Oxford said that the results “convincingly rule out any meaningful mortality benefit of lopinavir-ritonavir in the hospitalised COVID-19 patients we studied,” but added that the difficulty giving the drug to patients on ventilators meant they couldn’t draw conclusions on its effectiveness on such patients.
(Reporting by Alistair Smout, Editing by Franklin Paul)
